Sana Historical Balance Sheet
SANA Stock | USD 2.78 0.23 9.02% |
Trend analysis of Sana Biotechnology balance sheet accounts such as Other Liabilities of 129.7 M, Net Tangible Assets of 361.6 M, Property Plant And Equipment Net of 118.5 M or Accounts Payable of 2.1 M provides information on Sana Biotechnology's total assets, liabilities, and equity, which is the actual value of Sana Biotechnology to its prevalent stockholders. By breaking down trends over time using Sana Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Sana Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sana Biotechnology is a good buy for the upcoming year.
Sana |
About Sana Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Sana Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Sana Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sana Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sana currently owns. An asset can also be divided into two categories, current and non-current.
Sana Biotechnology Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Sana Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sana Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Sana Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Sana Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most accounts from Sana Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sana Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Other Current Liabilities is forecasted to decline to about 46 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 78.7M | 83.9M | 47.2M | 46.0M | Total Assets | 1.1B | 822.7M | 565.3M | 677.9M |
Sana Biotechnology balance sheet Correlations
Click cells to compare fundamentals
Sana Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sana Biotechnology balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 415.7M | 730.3M | 1.1B | 822.7M | 565.3M | 677.9M | |
Other Current Liab | 18.0M | 21.8M | 78.7M | 83.9M | 47.2M | 46.0M | |
Total Current Liabilities | 19.8M | 31.5M | 99.2M | 111.5M | 64.5M | 60.2M | |
Total Stockholder Equity | (142.5M) | (421.2M) | 728.5M | 499.3M | 287.5M | 172.0M | |
Other Liab | 74.7M | 198.9M | 199.9M | 116.0M | 133.4M | 129.7M | |
Net Tangible Assets | (342.4M) | (621.0M) | 528.7M | 299.5M | 344.4M | 361.6M | |
Property Plant And Equipment Net | 69.3M | 109.9M | 161.8M | 159.4M | 145.6M | 118.5M | |
Net Debt | (31.8M) | (340.1M) | (142.1M) | (68.5M) | (29.4M) | (30.9M) | |
Retained Earnings | (144.1M) | (429.4M) | (785.4M) | (1.1B) | (1.3B) | (1.3B) | |
Accounts Payable | 0.0 | 2.3M | 2.2M | 2.9M | 4.1M | 2.1M | |
Cash | 80.0M | 412.0M | 253.0M | 176.8M | 133.5M | 199.1M | |
Non Current Assets Total | 271.4M | 345.8M | 571.3M | 378.3M | 351.8M | 352.1M | |
Non Currrent Assets Other | 2.3M | 2.3M | 13.8M | 9.0M | 6.4M | 6.3M | |
Other Assets | 2.3M | 2.3M | 13.8M | 9.0M | 10.4M | 6.3M | |
Cash And Short Term Investments | 139.0M | 412.0M | 746.9M | 434.0M | 205.2M | 360.7M | |
Short Term Investments | 59.0M | 253.5M | 298.0M | 247.2M | 71.7M | 68.1M | |
Liabilities And Stockholders Equity | 415.7M | 730.3M | 1.1B | 822.7M | 565.3M | 677.9M | |
Non Current Liabilities Total | 538.4M | 1.1B | 301.7M | 211.9M | 213.3M | 324.1M | |
Capital Lease Obligations | 48.2M | 71.9M | 110.9M | 108.3M | 104.1M | 81.3M | |
Other Current Assets | 5.3M | 12.4M | 14.2M | 20.5M | 8.3M | 11.5M | |
Other Stockholder Equity | (415.8M) | 852.9M | 1.5B | 1.6B | 1.6B | 941.7M | |
Total Liab | 558.2M | 1.2B | 400.9M | 323.4M | 277.8M | 367.9M | |
Net Invested Capital | (142.5M) | (421.2M) | 728.5M | 499.3M | 287.5M | 172.0M | |
Property Plant And Equipment Gross | 69.3M | 109.9M | 180.6M | 193.4M | 187.4M | 135.9M | |
Total Current Assets | 144.3M | 384.5M | 558.1M | 444.4M | 213.5M | 325.9M | |
Accumulated Other Comprehensive Income | 26K | 30K | (1.4M) | (4.3M) | (60K) | (63K) | |
Capital Stock | 1K | 2K | 18K | 19K | 20K | 11K | |
Non Current Liabilities Other | 74.7M | 198.9M | 301.7M | 211.9M | 122.4M | 166.8M | |
Net Working Capital | 124.4M | 353.0M | 458.9M | 332.9M | 149.0M | 265.7M | |
Property Plant Equipment | 68.8M | 109.9M | 65.5M | 66.9M | 77.0M | 68.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.